Stocks and Investing Stocks and Investing
Fri, November 9, 2012
Thu, November 8, 2012

Market Maker Surveillance Report. CALI, PGNX, COBR, PSTI, BCRX, ENPH, Losing Stocks With Lowest Price Friction For Thursday, N


Published on 2012-11-08 18:00:50 - WOPRAI
  Print publication without navigation


November 8, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3642 companies with "abnormal" market making, 1640 companies with positive Friction Factors and 3847 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. China Auto Logistics Inc (NASDAQ:CALI), Progenics Pharmaceuticals Inc (NASDAQ:PGNX), Cobra Electronics Corp (NASDAQ:COBR), Pluristem Therapeutics Inc (NASDAQ:PSTI), BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), Enphase Energy Inc (NASDAQ:ENPH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  CALI    $-0.550   -24.44%   47,911       35.88%    85,617       64.12%    -37,706      -686    
  PGNX    $-0.710   -26.30%   277,813      47.43%    307,887      52.57%    -30,074      -424    
  COBR    $-1.350   -26.95%   60,559       32.24%    122,074      64.99%    -61,515      -456    
  PSTI    $-0.860   -23.31%   1,567,704    40.12%    2,340,032    59.88%    -772,328     -8,981  
  BCRX    $-1.000   -40.63%   1,859,798    45.80%    2,201,111    54.20%    -341,313     -3,413  
  ENPH    $-0.830   -25.30%   258,956      44.91%    315,150      54.65%    -56,194      -677    
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows CALI with a dollar loss Thursday of $-0.55000 and a Friction Factor of -686 shares. That means that it only took 686 more shares of selling than buying to move CALI lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

China Auto Logistics Inc (NASDAQ:CALI) - China Auto Logistics Inc., through its subsidiaries, engages in importing, selling, and trading automobiles in the Peoples Republic of China. It also provides financing services, including letter of credit issuance services, purchase deposit financing, and import duty advance services; logistic services relating to the automobile importing process; and other automobile import value added services, such as customs clearance, storage, and nationwide delivery services to imported automobile distributors and agents, as well as individual customers. In addition, the company operates two Websites, www.at160.com, which provides quotes and other information on domestically manufactured automobiles; and www.at188.com that offers information on imported automobiles for the industry and individuals. It sells vehicles to authorized dealers, free traders or wholesalers, government agencies, and individual customers. China Auto Logistics Inc. is based in Tianjin, the Peoples Republic of China..

Progenics Pharmaceuticals Inc (NASDAQ:PGNX) - Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company offers RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation in advanced illness patients receiving palliative care. It is also conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells, as well as in blood vessels supplying other solid tumors. In addition, the company is developing therapeutic vaccines designed to stimulate an immune response to PSMA; PRO 140, a viral-entry inhibitor for human immunodeficiency virus (HIV), which is in Phase II clinical testing; and novel multiplex PI3-Kinase inhibitors to combat aggressive forms of cancer. Additionally, it engages in researching a prophylactic vaccine for HIV infection; and candidates that are HCV-entry inhibitors. The company was founded in 1986 and is based in Tarrytown, New York..

Cobra Electronics Corp (NASDAQ:COBR) - Cobra Electronics Corporation engage in the design and marketing of two-way mobile communication products and mobile navigation products in the United States, Canada, and Europe. It operates in two segments, Cobra Consumer Electronics and Performance Products Limited. The Cobra Consumer Electronics segment offers two-way radios; integrated radar/laser detectors; Citizens Band radios; power inverters and jump starters; marine electronics; photo-enforcement and safety detection; and mobile navigation products. It sells its products directly to retailers, such as mass marketers, consumer electronics specialty stores, large department store chains, warehouse clubs, television home-shopping retailers, direct-response merchandisers, home centers, and specialty stores, as well as through two-step wholesale distributors that carry its products to fill orders for travel centers, truck stops, small department stores and appliance dealers, duty-free shops on cruise lines, and for export. The Performance Products Limited segment offers personal navigation devices under the trade names Snooper Truckmate, Snooper Syrius, Snooper Sapphire Plus, and Snooper Strabo; and GPS-enabled speed camera location detectors under the trade names Snooper Sapphire and Snooper Evolution, as well as proprietary AURA database that provides drivers with advance notice of upcoming speed camera and hazardous locations. This segment sells personal navigation, speed camera locator, and database products. The company was founded in 1961 and is based in Chicago, Illinois..

Pluristem Therapeutics Inc (NASDAQ:PSTI) - Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the companys proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The companys principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel..

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) - BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS). Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX-4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Durham, North Carolina..

Enphase Energy Inc (NASDAQ:ENPH) - .

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net


Contributing Sources